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Pulsenet-pulsed ﬁeld gel electrophoresis proﬁle SHADXB.0001 was
predominant in Greece (58%) as in Europe but PT1, a rare phage
type in Europe, was frequent in Greece (56%). The SHADXB.0001
and PT1 clone (38%) were found in humans, animals and food of
animal origin with R-type ApSpTNxpCp being predominant (25%).
The data indicate that this clone (possibly endemic) was circulating
through the food chain in Greece during the study period.
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E-mail: theoﬁlos23@vet.auth.grClinical Microbiology and Infection © 2014 European Society of CSalmonella enterica serovar Hadar (S. Hadar) has been targeted
by European Union regulations as one of the ﬁve serovars to be
reduced in prevalence in the European Union in poultry pop-
ulations [1]. In Greece, S. Hadar ranked between 0.65 and 2.9%
during 2007–2012 among human isolates [1]. Resistance to
antimicrobials used to treat invasive S. Hadar is reported less
frequently compared with other serovars; nonetheless, these
isolates have been described as a reservoir of antimicrobial
resistance [2]. In this study, all 120 S. Hadar strains isolated
from patients (n = 41), animals (n = 49) and food products (n =
30) from 2007 to 2010 in Greece were characterized by (a)
assessing phenotypic antimicrobial resistance proﬁles, (b) by
phage typing and (c) by genotyping using pulsed-ﬁeld gel elec-
trophoresis (PFGE) to evaluate the relationship of the strains.
Susceptibility to a panel of 20 antimicrobials was determined by
an agar dilution method in Isosensitest agar (Oxoid, Basing-
stoke, UK). The ﬁnal plate concentrations (mg/L) used routinely
by the Salmonella Reference Service, Public Health England
(formerly known as the Health Protection Agency, Colindale)
on the basis of long-term studies were: ampicillin (A) 8 and 128;
chloramphenicol (C) 8; colomycin (Co) 8; gentamicin (G) 4;
kanamycin (K) 16; neomycin (Ne) 8; streptomycin (S) 16 and
128; spectinomycin (Sp) 64; sulphonamide (Su) 64; tetracycline
(T) 8 and 128; trimethoprim (Tm) 2; ciproﬂoxacin (Cp) 0.125
and 1; nalidixic acid (Nx) 16; furazolidone (Fu) 8; amikacin (Ak)
4; cephalexin (Cx) 16; cephradine (Cr) 16; cefuroxime (Cf) 16;
ceftriaxone (Cn) 1; cefotaxime (Ct) 1. Multidrug-resistance was
deﬁned as previously proposed [3]. Growth of the organism
only to the low concentration plates is considered as low level
(p). Phage typing was performed on all isolates, according to the
protocol of the Salmonella Reference Service, Public Health
England [4]. PFGE was performed after digestion of genomic
DNA with XbaI (Takara, Tokyo, Japan) according to the Pulse-
Net protocol [5]. Fingerprints were analyzed using BIONUMERICS
v6.1 (Applied-Maths, Sint-Martens-Latem, Belgium) and sub-
mitted to the PulseNet Europe database for assigning proﬁle
names [6]. Dendrograms were constructed using the Dice
similarity coefﬁcient and the unweighted pair group method
with arithmetic averages (UPGMA), with optimization and po-
sition tolerance set at 1.5%.
Based on the antimicrobials tested, several multidrug-
resistant patterns were observed for the 120 S. Hadar iso-
lates with pattern ApSpTNxpCp predominating (64/120, 53%),
when all sources were considered together. (Table 1). The
overall resistance to ampicillin, streptomycin, tetracycline,
nalidixic acid and low level ciproﬂoxacin (0.125 mg/L) was 82%,
81%, 75%, 92% and 88%, respectively. High level resistance to
ciproﬂoxacin (1 mg/L) was not observed. Resistance to ceph-
alosporins was not detected.Clin Microbiol Infect 2015; 21: 149.e1–149.e4
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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TABLE 1. Salmonella enterica serovar Hadar resistance-types, corresponding pulsed-ﬁeld gel electrophoresis proﬁles and phage
types, Greece, 2007–2010 (n [ 120)
Resistance-type n (%) Origin
PFGE Phage typing
PFGE-type n (%) Origin Phage type n (%) Origin
ApSpTNxpCp 64 (53) 11H,
36P,
17F
SHADXB.0001 41 (34.2) 10H,
22P,
9F
PT 1 32 (26.7) 7H, 19P, 6F
PT 2 4 (3.3) 1H, 1P, 2F
PT 10 2 (1.7) 1P, 1F
PT 41 2 (1.7) 1H, 1P
PT 48 1 (0.8) 1H
SHADXB.0010 1 (0.8) 1P PT 1 1 (0,8) 1P
SHADXB.0014 1 (0.8) 1F PT 1 1 (0,8) 1P
Unnamed 21 (17.5) 1H,
13P,
7F
PT 1 13 (10.8) 9P, 4F
PT 10 4 (3.3) 2P, 2F
PT 2 2 (1.6) 1P, 1F
PT 39 1 (0.8) 1H
PT 41 1 (0.8) 1P
ANxpCp 14 (12) 12H,
1P,
1F
SHADXB.0001 9 (7.5) 8H, 1P PT 1 6 (5.0) 6H
PT 5 1 (0.8) 1 P
PT 21 2 (1.6) 2H
Unnamed 5 (4.2) 4H
1F
PT 1 2 (1.6) 2H
PT 5 1 (0.8) 1F
PT 30 1 (0.8) 1H
PT 41 1 (0.8) 1H
Other 42
(35.0)
18H,
12P,
12F
SHADXB.0001 20 (16.7) 6H
8P
6F
PT 1 9 (7.5) 3H, 4P, 2F
PT 41 3 (2.5) 1H, 1P, 1F
PT 12 3 (2.5) 3F
PT 4 1 (0.8) 1P
PT 10 1 (0.8) 1H
PT 28 1 (0.8) 1P
PT 46 1 (0.8) 1P
PT 48 1 (0.8) 1H
SHADXB.0006 3 (2.5) 3H PT 2 2 (1.6) 2H
PT 1 1 (0.8) 1H
SHADXB.0008 1 (0.8) 1P PT41 1 (0.8) 1P
Unnamed 18 (15.0) 9 H
3 P
6 F
PT 1 4 (3.3) 1H, 1P, 2F
PT 18 5 (4.2) 2H, 2P, 1F
PT 2 3 (2.5) 3F
PT 22 2 (1.6) 2H
PT 10 1 (0.8) 1H
PT 21 1 (0.8) 1H
PT 41 1 (0.8) 1H
UT 1 (0.8) 1H
Due to rounding, the sum of the percentages in a given category does not always equal to 100.
Abbreviations: PFGE, pulsed ﬁeld gel electrophoresis; A, ampicillin; S, streptomycin; T, tetracycline; Nx, nalidixic acid; Cp, ciproﬂoxacin; H, human; P, poultry; F, food; UT, untypable.
Note: Growth of the organism only to the low concentration plates is considered as low level (p).
149.e2 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIPhage typing of the 120 strains examined identiﬁed 17
different phage types (PTs) but one isolate was found to be
untypeable. When all sources were considered together, the
most frequently identiﬁed PTs were PT1 (67/120, 56%), PT2 (11/
120, 9%), PT41 (9/120, 7%) and PT10 (8/120, 7%). Although no
particular phage type was identiﬁed from a speciﬁc source,
predominant phage types were present in humans, poultry and
food. PFGE analysis identiﬁed 33 unique proﬁles (Fig. 1). Seventy-
six of 120 isolates (63.3%) were represented by ﬁve proﬁles
SHADXB.0001, SHADXB.0006, SHADXB.0008, SHADXB.0010
and SHADXB.0014 of the PulseNet identiﬁed proﬁles. The most
frequent PFGE proﬁle was SHADXB.0001 (70/120, 58.3%); this
proﬁle was identiﬁed among human, poultry and food isolates
and was present during every year from 2007 to 2010.
Combining resistance-type (R-type), PFGE proﬁle and phage
type of all isolates, the ApSpTNxpCp, SHADXB.0001 and PT1
cluster was predominant (32/120, 26.7%) (Table 1). This clone,
represented in humans (7/41), poultry (19/49) and food (6/30)
was the most frequently occurring clone in Greece.
Salmonella Hadar is one of the 15 most frequently identiﬁed
serovars of Salmonella isolated from humans and found in aClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectproportion of 1.5% in Europe during 2001–2007 [7]. In
Greece, S. Hadar ranked in the top ten serovars reported from
humans during the whole study period in a proportion between
1% and 3% [8]. Salmonella Hadar is mostly linked with poultry;
in USA during 1998–2008 eight reported outbreaks of S. Hadar
were linked with eggs, chicken and turkey meat [9].
The majority of strains were resistant to streptomycin,
nalidixic acid, tetracycline and ampicillin, but not to third-
generation cephalosporins. The considerable percentage
(85%) of multidrug-resistant strains in our collection is in
accordance with studies in Spain [10,11], but higher than in a
European multicentre study in 2000, which describes 37%
multidrug-resistant Salmonella isolates, as well as 47% from a
study in Switzerland during 2005 [12].
Resistance to nalidixic acid in Salmonellae has been reported
to be an indicator for reduced susceptibility to the drug of
choice, ciproﬂoxacin, resulting in possible treatment failure
[13]. Consequently, the 92% nalidixic acid-resistance found in S.
Hadar in this study must be considered as having reduced
susceptibility to ciproﬂoxacin, and so potentially increased
treatment resistance. Results from our study showed that S.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 149.e1–149.e4
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FIG. 1. Pulsed-ﬁeld gel electrophoresis proﬁles identiﬁed in isolates determined as Salmonella enterica serovar Hadar (n = 120), Greece, 2007–2010.
CMI Papadopoulos et al. Salmonella Hadar in Greece 2007–2010 149.e3Hadar PT1 and PT2 were most commonly detected, interest-
ingly PT1 is not the main type in many studies worldwide
[14,15] as usually the predominant type is PT2 [16].
SHADXB.0001 was, according to our results, the most com-
mon PFGE proﬁle in Greece, approximately 58% of the isolates,
as in Europe; 54% (n = 100) in England and Wales during 2001,
and 52% (n = 394) of S. Hadar human isolates from other Eu-
ropean countries (data not shown).
The results of this study provide enough evidence for the
zoonotic origin of S. Hadar clinical isolates through the food chain
in Greece. It seems that there is a particular clone (PFGE proﬁle
SHADXB.0001 and PT1) circulating between humans and poultry
in Greece, this clone represents around 47% of all S. Hadar iso-
lates and various resistance patterns have been acquired by this
clone during its evolution. It could be suggested that it is an
endemic clone as it has been isolated from hatcheries, breeder
ﬂocks, laying hens, broilers, food and humans and was found each
year during the study period. Surveillance of S. Hadar strains forClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inresistance to antimicrobial agents should be continued and
improved to identify potential emergence of new resistance pat-
terns. Future work could involve high-resolution typing methods
based on whole genome sequencing coupled with good epide-
miological and clinical data to detect source of infection.Transparency declarationThe authors declare no conﬂicts of interest.AcknowledgementsThe authors gratefully acknowledge the personnel of National
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